Business

The FINANCIAL -- AstraZeneca on March 27 announced that the China Food and Drug Administration (CFDA) has granted marketing authorisation for Tagrisso (osimertinib) 40 mg and 80mg once-daily oral tablets for the treatment of adult patients with locally-advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC) whose disease has ...

More Articles ...

More Articles ...

The FINANCIAL -- Novo Nordisk A/S on March 1 announced that Jakob Riis, executive vice president, head of North America Operations and president of Novo Nordisk Inc. has resigned from the ...

The FINANCIAL -- Astellas Pharma Inc. announced that it launched a guanylate cyclase-C (GC-C) receptor agonist, LINZESS Tablets for irritable bowel syndrome with constipation) (“IBS-C”) in Japan ...